Aseel Samaro

Dr. Aseel Samaro

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
GVG. Verstraete
G. Verstraete
ASAseel Samaro
Aseel Samaro
WGW. Grymonpré
W. Grymonpré
Valérie VanhoorneValérie Vanhoorne
Valérie Vanhoorne
BSB. Van Snick
B. Van Snick
CVChris Vervaet
Chris Vervaet

5 June 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Bahaa ShaqourBahaa Shaqour
Bahaa Shaqour
ASAseel Samaro
Aseel Samaro
BVBart Verleije
Bart Verleije
KBKoen Beyers
Koen Beyers
CVChris Vervaet
Chris Vervaet
PCPaul Cos
Paul Cos
Fused filament fabrication (FFF) 3D printing technology is widely used in many fields. For almost a decade, medical researchers have been exploring the potential use of this technology for improving the healthcare sector. Advances in personalized medicine have been more achievable due to the applicability of producing drug delivery devices, which are explicitly designed based on patients’ needs. For the production of these devices, a filament—which is the feedstock for the FFF 3D printer—consists of a carrier polymer (or polymers) and a loaded active pharmaceutical ingredient (API). This systematic review of the literature investigates the most widely used approaches for producing drug-loaded filaments. It also focusses on several factors, such as the polymeric carrier and the drug, loading capacity and homogeneity, processing conditions, and the intended applications. This review concludes that the filament preparation method has a significant effect on both the drug homogeneity within the polymeric carrier and drug loading efficiency.

1 August 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ASAseel Samaro
Aseel Samaro
PJP. Janssens
P. Janssens
VVV. Vanhoorne
V. Vanhoorne
JRJ. Van Renterghem
J. Van Renterghem
MEM. Eeckhout
M. Eeckhout
CVChris Vervaet
Chris Vervaet

26 July 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
TDTryfon Digkas
Tryfon Digkas
A. PorfireA. Porfire
A. Porfire
JRJeroen Van Renterghem
Jeroen Van Renterghem
ASAseel Samaro
Aseel Samaro
GBGheorghe Borodi
Gheorghe Borodi
Ioan TomutaIoan Tomuta
Ioan Tomuta
The present study aimed to develop 3D printed dosage forms, using custom-made filaments loaded with diclofenac sodium (DS). The printed tablets were developed by implementing a quality by design (QbD) approach. Filaments with adequate FDM 3D printing characteristics were produced via hot melt extrusion (HME). Their formulation included DS as active substance, polyvinyl alcohol (PVA) as a polymer, different types of plasticisers (mannitol, erythritol, isomalt, maltodextrin and PEG) and superdisintegrants (crospovidone and croscarmellose sodium). The physicochemical and mechanical properties of the extruded filaments were investigated through differential scanning calorimetry (DSC), X-ray diffraction (XRD) and tensile measurements. In addition, cylindrical-shaped and tubular-shaped 3D dosage forms were printed, and their dissolution behaviour was assessed via various drug release kinetic models. DSC and XRD results demonstrated the amorphous dispersion of DS into the polymeric filaments. Moreover, the 3D printed tablets, regardless of their composition, exhibited a DS release of nearly 90% after 45 min at pH 6.8, while their release behaviour was effectively described by the Korsmeyer–Peppas model. Notably, the novel tube design, which was anticipated to increase the drug release rate, proved the opposite based on the in vitro dissolution study results. Additionally, the use of crospovidone increased DS release rate, whereas croscarmellose sodium decreased it.

12 September 2022 in Materials Today Bio
Verified
Journal Article
Open access
ASAseel Samaro
Aseel Samaro
MVMaarten Vergaelen
Maarten Vergaelen
MPMartin Purino
Martin Purino
ATAli Tigrine
Ali Tigrine
VRVictor R. de la Rosa
Victor R. de la Rosa
CVChris Vervaet
Chris Vervaet
Sustaining the release of highly dosed APIs from a matrix tablet is challenging. To address this challenge, this study evaluated the performance of thermoplastic poly (2-alkyl-2-oxazoline)s (PAOx) as matrix excipient to produce sustained-release tablets via three processing routes: (a) hot-melt extrusion (HME) combined with injection molding (IM), (b) HME combined with milling and compression and (c) direct compression (DC). Different PAOx (co-)polymers and polymer mixtures were processed with several active pharmaceutical ingredients having different aqueous solubilities and melting temperatures (metoprolol tartrate (MPT), metformin hydrochloride (MTF) and theophylline anhydrous (THA)). Different PAOx grades were synthesized and purified by the Supramolecular Chemistry Group, and the effect of PAOx grade and processing technique on the in vitro release kinetics was evaluated. Using the hydrophobic poly (2-n-propyl-2-oxazoline) (PnPrOx) as a matrix excipient allowed to sustain the release of different APIs, even at a 70% (w/w) drug load. Whereas complete THA release was not achieved from the PnPrOx matrix over 24 ​h regardless of the processing technique, adding 7.5% w/w of the hydrophilic poly (2-ethyl-2-oxazoline) to the hydrophobic PnPrOx matrix significantly increased THA release, highlighting the relevance of mixing different PAOx grades. In addition, it was demonstrated that the release of THA was similar from co-polymer and polymer mixtures with the same polymer ratios. On the other hand, as the release of MTF from a PnPrOx matrix was fast, the more hydrophobic poly (2-sec-butyl-2-oxazoline) (PsecBuOx) was used to retard MTF release. In addition, a mixture between the hydrophilic PEtOx and the hydrophobic PsecBuOx allowed accurate tuning of the release of MTF formulations. Finally, it was demonstrated that PAOx also showed a high ability to tune the in vivo release. IM tablets containing 70% MTF and 30% PsecBuOx showed a lower in vivo bioavailability compared to IM tablets containing a low PEtOx concentration (7.5%, w/w) in combination with PsecBuOx (22.5%, w/w). Importantly, the in vivo MTF blood level from the sustained release tablets correlated well with the in vitro release profiles. In general, this work demonstrates that PAOx polymers offer a versatile formulation platform to adjust the release rate of different APIs, enabling sustained release from tablets with up to 70% w/w drug loading.

16 November 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Niloofar Moazami GoudarziNiloofar Moazami Goudarzi
Niloofar Moazami Goudarzi
ASAseel Samaro
Aseel Samaro
CVChris Vervaet
Chris Vervaet
Matthieu BooneMatthieu Boone
Matthieu Boone
Visualization of the dynamic behavior of pharmaceutical dosage forms during the dissolution process offers a better understanding of the drug release mechanism, enabling the design of customized dosage forms. In this study, an X-ray tomography-based approach is proposed to monitor and analyze the dynamics of the structure at the pore scale level during the dissolution process. A flow-through cell dissolution apparatus was developed, capable of mimicking the standard in vitro dissolution process, which can be easily positioned in an X-ray tomography setup. The method was utilized to study the dissolution of a Capa® (polycaprolactone)-based sustained-release 3D printed tablet. The impact of the flow rate on the active pharmaceutical ingredient (API) release rate was studied and 16 mL/min was selected as a suitable flow rate. Furthermore, cesium chloride (CsCl) was used as a contrast agent to increase the contrast between the sample and the dissolution medium. Data obtained with this novel technique were in a good agreement with the released drug rate acquired by the standard in vitro dissolution test (the similarity factor (f2) = 77%). Finally, the proposed approach allowed visualizing the internal structure of the sample, as well as real-time tracking of solution ingress into the product.